secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001628280-26-012238
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Pacira BioSciences reports Q4 2025 revenue of $196.9M, up 5%, and full-year 2026 guidance
--------------------------------------------------------------------------------

- Q4 2025 total revenue $196.9M (5% increase vs Q4 2024); EXPAREL sales $155.8M (+5%)
- Full-year 2025 revenue $726.4M; GAAP net income $7.0M vs net loss of $99.6M in 2024
- Repurchased 5.9M shares for $150.0M in 2025; $150M remaining authorization through Dec 2026
- 2026 guidance: EXPAREL net sales $600-620M, total revenue $745-770M, gross margin 77-79%
- Strategic partnership with LG Chem for EXPAREL in select Asian-Pacific markets; Samit Hirawat appointed to board

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/0001628280-26-012238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/pcrx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-012238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer